Jeffrey Weber

Consulting Medical Director at Altor BioScience Corp.

Jeffrey Weber

Jeffrey Weber

Consulting Medical Director at Altor BioScience Corp.

Overview
RelSci Relationships

2335

Number of Boards

9

Relationships
RelSci Relationships are individuals Jeffrey Weber likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chair, Medical Advisory Panel at Melanoma Research Alliance

Relationship likelihood: Strong

Executive Vice President at Translational Research In Oncology

Relationship likelihood: Strong

Co-Founder at Tango Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at SELLAS Life Sciences Group, Inc.

Relationship likelihood: Strong

Chair, Radiation Oncology at NYU Elaine A. & Kenneth G. Langone Medical Center

Relationship likelihood: Strong

Co-Founder at Strata Oncology, Inc.

Relationship likelihood: Strong

Chief of Hospital Operations at NYU Elaine A. & Kenneth G. Langone Medical Center

Relationship likelihood: Strong

Former Interim Chief Executive Officer & Chief Financial Officer at SELLAS Life Sciences Group, Inc.

Relationship likelihood: Strong

Lloyd J. Old-Virginia & Daniel K. Ludwig Chair in Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service, Director, Parker Institute for Cancer Immunotherapy, Msk & Associate Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Vice President & Associate Cancer Center Director of Translational Research at City of Hope - California

Relationship likelihood: Strong

Paths to Jeffrey Weber
Potential Connections via
Relationship Science
You
Jeffrey Weber
Consulting Medical Director at Altor BioScience Corp.
Education
Ph.D.

The Rockefeller University (the University) is a world renowned center for research (see schedule O) and graduate education in the biomedical sciences, chemistry, bioinformatics, and physics. The University's 77 laboratories conduct both basic and clinical research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Laboratories are loosely clustered in six research areas, including biochemistry, structural biology, and chemistry; medical sciences and human genetics; molecular, cell, and developmental biology; immunology, virology, and microbiology; neuroscience; and physics and mathematical biology. The University does not charge tuition. Its revenues are derived primarily from investment income, government grants and contracts, and private gifts and grants.

MD

NYU School of Medicine has a proud history that goes back to 1837 and includes initiation of and participation in many of the major events in American medicine through two centuries. In 1837, six years after the granting of the first University charter, the minutes of the meetings of the University Council contained the names of men suggested as professors for the chief branches of medical instruction. In 1841, the University Medical College was organized, and instruction was begun under the following: Surgery, Anatomy; Chemistry; Theory and Practice of Medicine; Institutes of Medicine and Materia Medical; Obstetrics and Diseases of Women and Children. Clinical instruction was started in Bellevue Hospital in 1847, and in 1861 Bellevue Hospital Medical College was founded when a college building was erected on the hospital grounds. With the passing of the years and a deepening conviction that the total medical enterprise should be placed in the scholarly setting of the University, it became clear that University Medical College and Bellevue Hospital Medical College would benefit by consolidating. Thus, the medical school became an integral part of New York University in 1898 under the name of University and Bellevue Hospital Medical College. In 1935 the name was changed to New York University College of Medicine and in 1960 to NYU School of Medicine. The School of Medicine celebrated its sesquicentennial year in 1991.

Career History
Co-Director, Melanoma Program & Head of Experimental Therapeutics
2015 - Current
Consulting Medical Director
2007 - Current

Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL.

Scientific Advisor
Current

Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody- based medicines for immunotherapy of cancer. It specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company was founded by Carl Arne Krister Borrebaeck in 2001 and is headquartered in Lund, Sweden.

Boards & Committees
Member, Scientific Advisory Board
Current

cCAM Biotherapeutics Ltd. engages in the development of immunotherapies for different cancer indications. Its cCAM's lead agent, CM-24, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. The company was founded in 2010 and is headquartered in Misgav, Israel.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jeffrey Weber. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jeffrey Weber's profile does not indicate a business or promotional relationship of any kind between RelSci and Jeffrey Weber.